• Everkind Wellness agreed on October 27, 2026, to acquire 100% of Razroze for up to CAD 250,000 in common shares.
• Closing consideration totals CAD 125,000, comprising 197,160 common shares at a deemed price of CAD 0.634 each.
• A further CAD 125,000 in common shares is payable upon meeting milestones, priced using the preceding five-day volume-weighted average price.
• The acquisition expands institutional research partnerships and brings proprietary conversational AI safety frameworks to support enhancements to the buyer's emotional wellness platform.
• Razroze's research programs include CAD 240,000 with Waterloo University and CAD 170,000 with CAMH and the University of Toronto.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everkind Wellness Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610280730NEWSFILECNPR____20261028_321367_1) on October 28, 2026, and is solely responsible for the information contained therein.